New inhaled COVID-19 vaccine by McMaster enters phase-2 trials in Canada. The vaccine aims to provide stronger, needle-free ...

One avenue for new vaccine development is mucosal vaccines. In theory, dosing the vaccine directly into the respiratory tract allows for robust antibody and T-cell responses where SARS-CoV-2 generally ...

Public health physician Dr. Marcy Ahun discusses vaccine delivery innovations, like the auto-disable syringe, that have ...

Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology is currently being evaluated in a phase 1 clinical study of the first needle-free COVID-19 vaccine, having demonstrated ...

Vaxxas, a clinical-stage biotechnology company, today announced it has secured a new patent from the United States patent office covering proprietary manufacturing technology for its novel vaccination ...

To compare EI with needle injection through these conventional routes, we used a formalin-inactivated Aichi/68 influenza virus to immunize BALB/c mice (n = 8 per group). For EI, the vaccine was ...